Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)
China · Delayed Price · Currency is CNY 25.98
-0.49 (-1.85%)
At close: Sep 2, 2026
SHE:301258 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,345 | 2,915 | 2,153 | 2,959 | 3,598 | - | |
Market Cap Growth | -28.01% | 35.37% | -27.24% | -17.76% | - | - |
Enterprise Value | 1,200 | 1,583 | 771 | 1,545 | 2,218 | - |
Last Close Price | 26.47 | 32.24 | 23.36 | 31.21 | 37.40 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 355.26 | 45.33 | 131.23 | 26.38 | 20.29 | - |
PS Ratio | 5.95 | 6.74 | 5.01 | 6.05 | 6.33 | - |
PB Ratio | 1.28 | 1.56 | 1.14 | 1.52 | 1.91 | - |
P/TBV Ratio | 1.32 | 1.62 | 1.18 | 1.54 | 1.93 | - |
P/FCF Ratio | - | - | - | 55.68 | 35.60 | - |
P/OCF Ratio | - | 43.76 | 45.74 | 31.23 | 23.80 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.04 | 3.66 | 1.80 | 3.16 | 3.90 | - |
EV/EBITDA Ratio | 52.20 | 40.34 | 19.66 | 10.38 | 10.54 | - |
EV/EBIT Ratio | - | - | - | 16.63 | 13.97 | - |
EV/FCF Ratio | - | - | - | 29.07 | 21.95 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
Debt / EBITDA Ratio | 0.04 | 0.03 | 0.04 | 0.02 | 0.01 | 0.10 |
Debt / FCF Ratio | - | - | - | 0.04 | 0.03 | 0.16 |
Net Debt / Equity Ratio | -0.62 | -0.68 | -0.71 | -0.73 | -0.75 | -0.45 |
Net Debt / EBITDA Ratio | -51.23 | -32.11 | -34.31 | -9.52 | -6.74 | -1.83 |
Net Debt / FCF Ratio | 7.25 | 15.77 | 23.11 | -26.66 | -14.03 | -2.82 |
Asset Turnover | 0.19 | 0.21 | 0.20 | 0.23 | 0.37 | 0.59 |
Inventory Turnover | 2.42 | 2.49 | 2.23 | 2.15 | 3.29 | 4.88 |
Quick Ratio | 8.19 | 6.86 | 9.98 | 13.23 | 10.13 | 2.56 |
Current Ratio | 9.23 | 7.63 | 11.10 | 14.71 | 11.01 | 2.98 |
Return on Equity (ROE) | 0.35% | 3.43% | 0.86% | 5.85% | 13.49% | 17.61% |
Return on Assets (ROA) | -0.75% | -0.23% | -0.27% | 2.76% | 6.47% | 9.74% |
Return on Invested Capital (ROIC) | -3.04% | -1.15% | -1.54% | 16.26% | 31.73% | 29.30% |
Return on Capital Employed (ROCE) | -1.30% | -0.40% | -0.50% | 4.60% | 8.10% | 17.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.28% | 2.21% | 0.76% | 3.79% | 4.93% | - |
FCF Yield | -6.74% | -2.74% | -2.71% | 1.80% | 2.81% | - |
Dividend Yield | 0.85% | 0.68% | 0.39% | 1.92% | 1.55% | - |
Payout Ratio | 295.26% | 12.85% | 335.10% | 47.39% | 20.83% | 0.36% |
Buyback Yield / Dilution | 1.25% | 0.65% | 0.88% | -6.83% | -25.31% | 0.17% |
Total Shareholder Return | 2.10% | 1.33% | 1.27% | -4.91% | -23.76% | 0.17% |